COVID-19 vaccine developed by the Unversity of Oxford and British-Swedish firm AstraZeneca has recently started its final trial in Brazil.
All eyes are on Oxford's coronavirus vaccine as it has already shown promising results in the first phase of clinical human trial.
The researchers said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. “We are seeing good immune response in almost everybody," said Dr Adrian Hill, director of the Jenner Institute at Oxford University.